Summary TGF-,B is the prototype of a large family of multifunctional regulatory proteins. The 
inhibitory effects of TGF-# by a variety of mechanisms including inability to activate the latent form of the peptide, loss of cellular receptors for TGF-fl, and loss of functional intracellular signal transduction pathways.
Transforming growth factor-# (TGF-f,) is the prototype of a large family of multifunctional peptides. First purified to homogeneity in 1983 (Assoian et al., 1983; Frolik et al., 1983; Roberts et al., 1983) , and cloned in 1985 (Derynck et al., 1985) , it is one of the newest of the set of polypeptide growth factors which are now recognized as having central roles in controlling cellular activities. Yet the almost universal range of target cells for TGF-,B, the breadth of the scope of biological activities which it controls, and its high degree of evolutionary conservation, have resulted in recognition of TGF-f as a principal regulator of many physiological and pathological processes. In this brief review, we will present data relating to a multifaceted role for TGF-f in embryogenesis and the normal processes of inflammation and repair, as well as in pathological diseases such as cancer (for other reviews see Sporn et al., 1987; Roberts et al., 1988) .
Chemistry of TGF-f3J and 2 TGF-# is now known to exist principally in two homologous forms, called TGF-#l and TGF-#2 (Cheifetz et al., 1987) , with TGF-#l usually more abundant than TGF-,B2. TGF-,BI is a homodimeric peptide of 25,000 M, each chain of which is encoded as a 390 amino acid precursor and subsequently processed to a C-terminal 112 amino acid fragment (Derynck et al., 1985) . TGF-#2 is encoded as a somewhat larger precursor of 414 amino acids, but is also processed to a 112 amino acid fragment that is 71% homologous to TGF-ll (Marquardt et al., 1987; de Martin et al., 1987) . Conservation of each of these two peptides is very strong.
The mature TGF-#l peptide is identical in man, cow, pig, and monkey and differs by only one amino acid in mouse; the N-terminal 30 amino acids of mature TGF-#2 are also identical in man, cow, and pig. In most biological systems, TGF-f,l and 2 can act interchangeably, but distinct actions are beginning to be found, as well (Ohta et al., 1987; Rosa et al., 1988 ; see also Sporn & Roberts, 1988a) .
TGF-,ll is found in highest amounts in platelets (Assoian et al., 1983) and in bone (Seyedin et al., 1985) suggesting that it might play a major role in tissue repair and bone remodeling. The major proportion of the TGF-,ll released from platelets or from cells is in a biologically inactive 'latent' form that must be activated before it can interact with its receptor. Since acidification is the principal mode of activation of the latent form in vitro (Lawrence et al., 1985) , TGF-,ll that has been purified from platelets by steps involving low pH is permanently activated. Recent work by Wakefield et al. (1987a) demonstrates that the latent complex of TGF-#l results from association of the remaining portion of the TGF-#l precursor with the processed dimer. TGF-fl2 also exists in a latent form (Conner et al., 1988; Danielpour et al., 1988) ; whether or not it will also be found to be complexed with the corresponding portion of its precursor remainder remains to be determined. Activation of the latent forms of TGF-#1 and 2 possibly represents the principal physiological control mechanism of TGF-fl activity (Wakefield et al., 1987a) . What the actual physiological mechanisms of activation might be and whether distinct mechanisms might be operative for activation of TGF-fll and 2 are important questions.
Family of TGF-f peptides
Over the last two years, several proteins have been described which clearly have evolved from the same ancestral gene as the TGF-fls. These proteins, which are listed in Table I and include the mammalian peptides Mullerian inhibitory substance (MIS), the inhibins, and the activins, as well as the putative products of the DPP-C gene in Drosophila and the Vgl gene in Xenopus, belong to the TGF-fl family, based on the homologous positioning of 7-9 of the cysteine residues of TGF-f (the monomeric unit of TGF-# contains 9 cysteine residues). Like the TGF-fs, each of these proteins is encoded as a larger precursor and, with the exception of MIS, subsequently processed to a C-terminal monomeric unit of 100-134 amino acids. The homology among family members is confined to these processed, C-terminal peptides, which, in all cases known thus far, are biologically active only in homodimeric form (the putative products of the DPP-C and Vgl genes have not yet been isolated).
With the exception of TGF-#l and 2, which share some receptor cross-reactivity (Cheifetz et al., 1987; Segarini et al., 1987) , each of the family members is thought to act through distinct membrane receptors and each has a unique function (Table I) . However, despite these differences, many of these peptides have in common that they control aspects of development: thus MIS controls regression of the female anlage of the embryonic male reproductive system; the inhibins and activins presumably play a role in sexual maturation and sexual cycle in females; the product of the DPP-C gene controls dorsal-ventral patterning in Drosophila, and the product of the Vgl gene is thought to function in induction of mesoderm from amphibiam ectoderm. As will be discussed below, TGF-ll and 2 also play critical roles in embryogenesis, though the exact mechanisms are not yet understood. (Tucker et al., 1984; . Thus the activity of the peptide is not an intrinsic property of that factor, but is defined by the entire set of conditions operant on the cell. Some of the conditions which can alter the apparent effect of TGF-# on growth of fibroblastic cells are outlined in Table III ; these include the type of cell, the growth conditions, the total set of growth factors present, as well as the state of differentiation of the cells. These additional levels of complexity serve to greatly increase the spectrum of cellular responses to a relatively small number of peptide growth factors.
Role of TGF-f3 in embryogenesis As discussed earlier, one common thread linking the actions of peptides belonging to the TGF-f family is their effects on various aspects of embryonic development. Recent immunohistochemical studies of TGF-#l in the developing mouse embryo, undertaken in our laboratory, now clearly show that TGF-#l also plays a critical role in mammalian embryogenesis (Heine et al., 1987) . Northern blot analysis of TGF-#l mRNA levels during mouse embryogenesis showed that message levels were high throughout embryonic development, in contrast to genes such as those for TGFalpha, fibronectin, and type I collagen, which were more highly expressed in the early, middle, and late periods of gestation, respectively. Earlier studies had shown that TGFfl-like activity could be found in extracts of mouse embryos (Proper et al., 1982; Hill et al., 1986b) , but only a limited amount of information was available regarding the immunolocalization of TGF-#1 in the embryo (Ellingsworth et al., 1986) . The results of the immunohistochemical studies clearly demonstrate that TGF-Jl is expressed in a unique pattern, both spatially and temporally, in the developing mouse embryo (Heine et al., 1987) . Overall, TGF-fl was most highly associated with tissues derived from mesenchyme, such as connective tissue, cartilage, and bone. At days 13-15 of gestation, staining was particularly conspicuous in tissues derived from neural crest mesenchyme, such as the developing palate, larynx, facial mesenchyme, nasal sinuses, meninges, and teeth. In many tissues, the staining pattern appears to correlate with specific morphogenetic and histogenetic events, particularly those involving cells and tissues of mesenchymal or mesodermal origin; for example, intense staining of TGF-,B is seen during formation of the digits from limb buds, the formation of the palate, and formation of the heart valves. In addition, TGF-# staining was found in tissues in which critical mesenchymal-epithelial interactions occur (Hay, 1981) , such as in the formation of the hair follicles and teeth, the submandibular gland, and the intestine. As an example, in the snout, diffuse TGF-,ll staining is seen at early stages before formation of the hair follicles of the vibrissae; at day 15, staining is concentrated in the mesenchyme surrounding the follicles, and at day 18, when the follicles have matured, no more staining is seen.
Although these studies were focused on the relatively later stages of embryogenesis where organogenesis was occurring, Centrella et al. (1987) generation of cytotoxic Ranges et al. (1987) T-lymphocytes (Robey et al., 1987) ; inhibits growth of fibroblasts . 2. the growth conditions stimulates growth of NRK cells in soft agar; inhibits growth of NRK cells in monolayer culture . 3. the total set of growth factors acting on the cell stimulates growth of myc-FR3T3 cells in the presence of PDGF; inhibits their growth in the presence of EGF .
4. the state of differentiation of the cell stimulates growth of early human embryo fibroblasts; inhibits growth of later stage embryo fibroblasts (Hill et al., 1986a Role of TGF-f3 in granulation tissue and tumour stroma It has often been suggested that there is a common basis between wound healing and carcinogenesis (Haddow, 1972; Dvorak, 1986 (Dvorak, 1986 Effects of TGF-# on lymphocytes are uniformly inhibitory. TGF-f inhibits the proliferation of both T- (Kehrl et al., 1986b) and B-lymphocytes (Kehrl et al., 1986a) , and blocks antibody secretion by B cells. It also is inhibitory to other lymphocyte subtypes including natural killer cells (Rook et al., 1986) and lymphokine-activated killer cells (Mule et al., 1988 (Wrann et al., 1987) .
Effects of TGF-# on endothelial cells are complicated in that most of the in vitro effects are growth inhibitory (see for example Baird & Durkin, 1986 ), yet the peptide is angiogenic in vivo . In an in vitro assay system in whic endothelial cells are grown in a collagen matrix, it has been shown that TGF-# can induce tube formation, in the absence of cellular proliferation (Madri et al., 1988) . The higher order tissue architecture of capillary formation requires more than simple proliferation of cells, and it cannot be ruled out that TGF-# will be found to affect this organizational process and possibly also stimulate indirectly the proliferation of the cells via growth factors secreted by macrophages which it can attract and activate. Effects of TGF-,B on fibroblasts are multifaceted and constitiute, perhaps, the most unique and important aspects of TGF-f biology. As found for monocytes, TGF-# is chemotactic for fibroblasts, although at slightly higher concentrations (1Opgml-1; Postlethwaite et al., 1987) .
Again, higher concentrations of TGF-f8 activate fibroblasts, in this case to synthesize and accumulate matrix proteins. It is now clear that TGF-f, acts at three different levels to control accumulation of matrix proteins (for reviews see Sporn et al., 1987; Roberts et al., 1988) . The first mechanism whereby TGF-fl acts to increase accumulation of matrix proteins such as collagen and fibronectin is by directly increasing their synthesis (Ignotz & Massague, 1986; Roberts et al., 1986; . Recent studies using constructs of the promotor of mouse alpha 2(I)collagen have shown that treatment of cells with either TGF-fll or 2, but not with PDGF or EGF, results in transcriptional activation of the promotor (Rossi et al., 1988) . Deletion analysis has identified a short stretch of nucleotides known to mediate binding of a transcription factor, nuclear factor 1 (NF-1), which are required for the inductive effects of TGF-# on collagen gene expression.
Whether NF-I will also mediate the effects of TGF-,B on expression of other genes such as protease inhibitors is a problem of intense interest.
The second mechanism whereby TGF-# acts to control accumulation of matrix proteins is by control of their proteolytic degradation. This occurs both by decreased synthesis and secretion of proteases and by increased synthesis and secretion of protease inhibitors. As an example, treatment of fibroblasts with TGF-1I results in decreased secretion of the serine protease plasminogen activator as well as increased secretion of plasminogen activator inhibitor (Laiho et al., 1986) . Levels of the thiol protease, major excreted protein (Chiang & Nilsen-Hamilton, 1986) , and of the metalloproteases, stromelysin and collagenase (Matrisian et al., 1986; Edwards et al., 1987) have also been found to decrease, while increases have been found in the levels of tissue inhibitor of metalloproteineases (Edwards et al., 1987) . Once the promoters for these genes are isolated, it will be exciting to test whether regulation of their expression by TGF-fl, like that of the genes for the matrix proteins, themselves, might also be mediated by a NF-1 binding site.
Finally, recent experiments by have shown that there is yet a third mechanism whereby TGF-f controls aspects of matrix protein biology; treatment of cells with TGF-,B has been shown to result in increased a synthesis of the receptor for fibronectin, and possibly for other integrins as well. These three mechanisms, which assure both increased synthesis and increased response to matrix proteins, are probably central to the increases in connective tissue proteins associated with both healing and carcinogenesis, as well as to many of the effects of TGF-f on cell growth and differentiation both in vitro and in embryogenesis.
Immunohistochemical analyses of TGF-f,l in a severely dysplastic villoglandular polyp from human colon ( Figure  la) and in a hepatic granuloma (Figure lb) induced in rats by systemic injection of Group A streptococcal cell walls (Allen et al., 1985) show a similar pattern of stromal staining. In each case, the staining is associated with extracellular matrix and is in a region where fibroblasts and/or inflammatory cells predominate. The antibody used for these studies (Ellingworth et al., 1986) has been found to stain principally extracellular rather than intracellular TGF-f,1, suggesting that the staining pattern reflects areas of deposition of TGF-31, rather than sites of synthesis (unpublished). The staining pattern is consistent with secretion of TGF-fl by activated inflammatory cells (Assoian et al., 1987; Wahl et al., 1987) and premalignant colon adenomas (Wigley et al., 1986 ) and colon cancer cell lines (Coffey et al., 1987) . The similar staining patterns of these two sections, one of granulation tissue and one of a premalignant dysplastic lesion, are consistent with the common nature of these two tissues as discussed above.
Loss of negative autocrine growth control by tumour cells
In terms of a model for TGF-f action in carcinogenesis, it is known that most tumour cells express TGF-,B mRNA (Derynck et al., 1987) in stimulation of the growth of the tumour with accompanying stimulation of the development of supporting tumour stromal elements. However, autocrine effects of the secreted growth factors on the tumour cells themselves must also be considered. Whereas secretion by the tumour cells of growth factors such as PDGF (Johnsson et al., 1985) or bombesin (Cuttitta et al., 1985) has a positive autocrine effect, in vitro experiments have shown that the growth of many tumour cells can be inhibited by addition of TGF-f Moses et al., 1985; Wollenberg et al., 1987) . Thus, in terms of the proposed model (Figure 2 ), a contradiction arises with respect to the role of TGF-# in carcinogenesis. The resolution is that growth of tumour cells need not be affected directly by TGF-,B; rather growth of the tumour can be stimulated indirectly by TGF-# via its effects on formation of supporting tumour stroma. In fact, loss of responsiveness to growth inhibitory factors, such as TGF-fi, has been proposed as a contributing mechanism to the uncontrolled growth characteristics of neoplasms .
There are at least three ways by which tumour cells might lose their responsiveness to negative growth control by secreted TGF-fl: (1) cells could lose the ability to activate latent TGF-fl; (2) altered signalling mechanisms could result in inability to properly interpret the signal generated by interaction of TGF-f with its receptor, and (3) cells could lose their receptors for TGF-,B. Examples can now be cited for the first two mechanisms, and it is expected that examples of the third will also be found. A-549 human lung carcinoma cells divide at a high rate even though they secrete substantial amounts of latent TGF-,B. The growth of these cells is potently inhibited by either exogenous TGF-fl, or by their own conditioned medium, after the TGF-,B in that medium has been activated by treatment with acid (Wakefield et al., 1987b) . Thus these cells, by their inability to activate the latent TGF-,B they secrete, have escaped from that mechanism of growth control. Other transformed cells, in contrast to their non-transformed counterparts, have lost the ability to be inhibited by activated TGF-#, suggesting that transformation has altered a step in the TGF-,B signalling pathway (Lechner et al., 1983; McMahon et al., 1986; Shipley et al., 1986) .
In summary, it must be kept in mind that tumour cells secrete many growth factors, and that many of these such as PDGF (Johnsson et al., 1985) and bombesin (Cuttitta et al., 1985) have direct positive autocrine effects on the growth of the tumour cells. However, in the particular case of secretion by tumour cells of TGF-,B, which most often inhibits their growth, we propose, as shown in Figure 2 , that tumour cells lose the ability to interact with the peptide in an autocrine fashion, and instead, indirectly support their growth by paracrine action of the TGF-# they secrete on the supporting stromal elements. 
